Cancer cells enter a reversible drug-tolerant persister (DTP) state to evade death from
chemotherapy and targeted agents. It is increasingly appreciated that DTPs are important …

Accumulating preclinical and clinical evidence indicates that high degrees of heterogeneity
among malignant cells constitute a considerable obstacle to the success of cancer therapy …

The advent of targeted therapies has led to tremendous improvements in treatment options
and their outcomes in the field of oncology. Yet, many cancers outsmart precision drugs by …

Patient-derived tumor organoids have been established as promising tools for in vitro
modelling of multiple tumors, including cholangiocarcinoma (CCA). However, organoids are …

Most models of cancer cell population expansion assume exponential growth kinetics at low
cell densities, with deviations to account for observed slowing of growth rate only at higher …

Patient‐derived organoids (PDOs) represent promising preclinical models in various tumor
types. In the context of prostate cancer (PCa), however, their establishment has been …

Chimeric antigen receptor (CAR) T cell therapy is a remarkably effective immunotherapy that
relies on in vivo expansion of engineered CAR T cells, after lymphodepletion (LD) by …

Tumor growth is the result of the interplay of complex biological processes in huge numbers
of individual cells living in changing environments. Effective simple mathematical laws have …

Standard infectious disease practice calls for aggressive drug treatment that rapidly
eliminates the pathogen population before resistance can emerge. When resistance is …

In this work, we develop a kinetic model of tumour growth taking into account the effects of
clinical uncertainties characterising the tumours' progression. The action of therapeutic …